Role of mycophenolate mofetil in the treatment of lupus nephritis

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 5, 2007, Pages 879-882

  Contreras, Gabriel ^a   Sosnov, Jonathan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; ENZYME INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NOTE;

ENZYME INHIBITORS; HUMANS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID;

EID: 34548833852     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02740707     Document Type: Editorial

References (34)

1. Cameron JS: Lupus nephritis. J Am Soc Nephrol 10: 413-424, 1999
2. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D: Longterm follow-up of patients with lupus nephritis: A study based on the classification of the World Health Organization. Am J Med 83: 877-885, 1987
3. Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C, Iqbal K, Lenz O, Asif A, Nahar N, Leclerq B, Leon C, Schulman I, Ramirez-Seijas F, Paredes A, Cepero A, Khan T, Pachon F, Tozman E, Barreto G, Hoffman D, Almeida Suarez M, Busse JC, Esquenazi M, Esquenazi A, Garcia Mayol L, Garcia Estrada H: Factors associated wit poor outcomes in patients with lupus nephritis. Lupus 14: 890-895, 2005
4. Korbet SM, Schwartz MM, Evans J, Lewis EJ: Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol 18: 244-254, 2007
5. Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC: Renal damage in systemic lupus erythematosus: A comparative analysis of different age groups. Lupus 16: 28-34, 2007
6. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614-619, 1986
7. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992
8. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: A randomized, controlled trial. Ann Intern Med 125: 549-557, 1996
9. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT: Combination therapy with pulse cyclophosphamide plus pulse methyl-prednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135: 248-257, 2001
10. Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34: 945-950, 1991
11. Bansal VK, Beto JA: Treatment of lupus nephritis: A metaanalysis of clinical trials. Am J Kidney Dis 29: 193-199, 1997
12. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC: Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis 43: 197-208, 2004
13. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH; Dutch Working Party on Systemic Lupus Erythematosus: Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis: A randomized controlled trial. Kidney Int 70: 732-742, 2006
14. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980, 2004
15. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121-2131, 2002
16. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH: Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 7: 161-166, 1990
17. Allison AC, Hovi T, Watts RW, Webster AD: Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 2: 1179-1183, 1975
18. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ: Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067-1069, 1972
19. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85-118, 2000
20. Eugui EM, Almquist SJ, Muller CD, Allison AC: Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion Scand. Scand J Immunol 33: 161-173, 1991
21. Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 33: 175-183, 1991
22. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G: Mycophenolate mofetil limits renal damage and prolongs life in murine lupus; autoimmune disease. Kidney Int 51: 1583-1589, 1997
23. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH: Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 9: 1407-1415, 1998
24. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343: 1156-1162, 2000
25. Chan TM, Tse KC, Tang CS, Mok MY, Li FK: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16: 1076-1084, 2005
26. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L: Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 115: 705-709, 2002
27. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalh R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z: Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10: 504-510, 2005
28. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219-2228, 2005
29. Flores-Suarez LF, Villa AR: Open randomized trial comparing mycophenolate mofetil versus intravenous cyclophosphamide as induction therapy for severe lupus nephritis. J Am Soc Nephrol 15: P0257, 2004
30. Walsh M, James M, Jayne D, Tonelli M, Marms BJ, Hemmelgarn BR: Mycophenolate mofetil for induction therapy of lupus nephritis: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2: 968-975, 2007
31. Moore RA, Derry S: Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 8: R182, 2006
32. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS: Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50: 2559-2568, 2004
33. ALMS: Aspreva Lupus Management Study. Available at: http:// www.almstudy.com. Accessed June 6, 2007
34. Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis. Available at: http://clinicaltrials.gov/ct/show/ NCT00204022;jsessionid=95F7CD63B7CAE2A25DCD8D97CFE4EOF6?order=12. Accessed June 6, 2007